News from the Scientific Community

Here, we will regularly be posting links to articles or news we find interesting and which relate to functional drug sensitivity testing and associated industries. It is by no means intended as an exhaustive list of articles, but provides an indication of some of the most important developments in our space.

Cancer in general

• Hallmarks of Cancer: New Dimensions
• Precision Oncology: Between Vaguely Right and Precisely Wrong

Current (gene-based) approaches to Precision Oncology

• Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
• Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
• Molecular screening to select therapy for advanced cancer
• Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Decision-making in Healthcare

• The ecosystem of health decision making: from fragmentation to synergy

Functional drug sensitivity testing

• Functional Drug Screening in the Era of Precision Medicine
• Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations
• Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
• Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy

Guidelines

• Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up